tiprankstipranks
Advertisement
Advertisement
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
PremiumCompany AnnouncementsHeron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
2M ago
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
Premium
Company Announcements
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
2M ago
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
Premium
The Fly
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
3M ago
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
PremiumCompany AnnouncementsHeron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
4M ago
Heron Therapeutics Signals Recovery Despite Soft Q1
Premium
Company Announcements
Heron Therapeutics Signals Recovery Despite Soft Q1
4M ago
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
Premium
The Fly
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
4M ago
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus
PremiumCompany AnnouncementsHeron Therapeutics Strengthens Executive Contracts Amid Strategic Focus
5M ago
Heron Therapeutics Signals Profitable Growth After Strong Quarter
Premium
Company Announcements
Heron Therapeutics Signals Profitable Growth After Strong Quarter
6M ago
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target
Premium
Ratings
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100